Biomarker ID | 591 |
PMID | 21305254 |
Year | 2011 |
Biomarker | Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Desmin (DES); Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1); Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Stage T3(Fold Change) : Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.165]; Desmin (DES) [8.929]; Enoyl CoA hydratase, short chain, 1, mitochondrial (ECHS1) [7.407]; Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa) (HSPA5) [1.613]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(ARHGDIA):-Axonogenesis regulation by p75 neurotrophin receptor,Axonal growth stimulation,RhoA activity regulation,Vasopressin-regulated water reabsorption, Rac1 cell motility signaling pathway Pathways Include(DES):- Striated muscle contraction, Aurora B signaling, Muscle contraction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Dilated cardiomyopathy |
Experiment | Stage T2 Vs Stage T3 |
Type of Biomarker | Prognostic |
Cohort | Samples from 16 patients diagnosed with BPH along woth 8 patients with prostate cancer were chosen. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | MALDI-TOF-MS |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | ARHGDIA, DES, ECHS1, HSPA5, KRT18, KRT19, KRT8 |